ZA200604971B - 3-Cyano-quinoline derivatives with antiproliferative activity - Google Patents

3-Cyano-quinoline derivatives with antiproliferative activity

Info

Publication number
ZA200604971B
ZA200604971B ZA200604971A ZA200604971A ZA200604971B ZA 200604971 B ZA200604971 B ZA 200604971B ZA 200604971 A ZA200604971 A ZA 200604971A ZA 200604971 A ZA200604971 A ZA 200604971A ZA 200604971 B ZA200604971 B ZA 200604971B
Authority
ZA
South Africa
Prior art keywords
cyano
antiproliferative activity
quinoline derivatives
quinoline
derivatives
Prior art date
Application number
ZA200604971A
Other languages
English (en)
Inventor
Freyne Eddy Jean Edgard
Van Emelen Kristof
Timothy Pietro Suren Perera
Peter Jacobus Johannes Antonius Buijnsters
Werner Constan Johan Embrechts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34684508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200604971(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA200604971B publication Critical patent/ZA200604971B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA200604971A 2003-12-18 2006-06-15 3-Cyano-quinoline derivatives with antiproliferative activity ZA200604971B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EPPCT/EP03/51059 2003-12-18

Publications (1)

Publication Number Publication Date
ZA200604971B true ZA200604971B (en) 2009-05-27

Family

ID=34684508

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200604971A ZA200604971B (en) 2003-12-18 2006-06-15 3-Cyano-quinoline derivatives with antiproliferative activity

Country Status (23)

Country Link
US (4) US7655642B2 (uk)
EP (1) EP1696914B1 (uk)
JP (1) JP4892353B2 (uk)
KR (1) KR101158440B1 (uk)
CN (1) CN1893944B (uk)
AR (1) AR047060A1 (uk)
AT (1) ATE446750T1 (uk)
AU (1) AU2004298784B2 (uk)
BR (1) BRPI0417609B8 (uk)
CA (1) CA2549728C (uk)
DE (1) DE602004023876D1 (uk)
EA (1) EA200601176A1 (uk)
ES (1) ES2335216T3 (uk)
HK (1) HK1095742A1 (uk)
IL (1) IL176358A (uk)
MX (1) MXPA06007018A (uk)
NO (1) NO337622B1 (uk)
NZ (1) NZ547795A (uk)
SG (1) SG151288A1 (uk)
TW (2) TWI374879B (uk)
UA (1) UA83880C2 (uk)
WO (1) WO2005058318A1 (uk)
ZA (1) ZA200604971B (uk)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2305887T3 (es) * 2003-12-18 2008-11-01 Janssen Pharmaceutica Nv Derivados de pirido y pirimidopirimidinas como agentes antiproliferativos.
KR101158440B1 (ko) * 2003-12-18 2012-07-06 얀센 파마슈티카 엔.브이. 항증식활성을 지닌 3-시아노-퀴놀린 유도체
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
US10517876B2 (en) 2005-11-16 2019-12-31 Cti Biopharma Corp. Oxygen linked pyrimidine derivatives
JP5380073B2 (ja) * 2005-11-16 2014-01-08 エス*バイオ プライベート リミティッド ヘテロアルキル結合ピリミジン誘導体
AU2007274284B2 (en) * 2006-07-13 2012-04-26 Janssen Pharmaceutica N.V. Mtki quinazoline derivatives
JPWO2008087736A1 (ja) * 2007-01-19 2010-05-06 宇部興産株式会社 アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法
CA2687909C (en) * 2007-06-21 2015-09-15 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
JP5536647B2 (ja) 2007-07-27 2014-07-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピロロピリミジン
CN102127087B (zh) * 2011-01-21 2012-07-04 江苏先声药物研究有限公司 喹唑啉衍生物
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
MX2018004109A (es) 2015-10-05 2018-09-27 Univ Columbia Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028613A (en) 1990-02-16 1991-07-02 Repligen Corporation Novel pyrroloquinoline alkaloids and methods of use
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
PT1117659E (pt) 1998-09-29 2004-04-30 Wyeth Corp Cianoquinolinas substituidas como inibidores de tirosina-quinases de proteinas
AU2003226705B2 (en) * 2002-03-30 2008-11-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-(N-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
JO2785B1 (en) 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
KR101158440B1 (ko) 2003-12-18 2012-07-06 얀센 파마슈티카 엔.브이. 항증식활성을 지닌 3-시아노-퀴놀린 유도체

Also Published As

Publication number Publication date
KR20070005560A (ko) 2007-01-10
CA2549728C (en) 2015-07-21
US20130197022A1 (en) 2013-08-01
WO2005058318A1 (en) 2005-06-30
HK1095742A1 (en) 2007-05-18
US20080139601A1 (en) 2008-06-12
TWI374879B (en) 2012-10-21
JP4892353B2 (ja) 2012-03-07
MXPA06007018A (es) 2006-08-31
BRPI0417609B1 (pt) 2019-02-19
US20140256948A1 (en) 2014-09-11
BRPI0417609A (pt) 2007-04-10
EA200601176A1 (ru) 2006-10-27
SG151288A1 (en) 2009-04-30
JP2007514711A (ja) 2007-06-07
US9365517B2 (en) 2016-06-14
TWI389890B (zh) 2013-03-21
AU2004298784B2 (en) 2011-06-09
IL176358A (en) 2010-06-16
NO20063324L (no) 2006-07-18
NZ547795A (en) 2009-07-31
CA2549728A1 (en) 2005-06-30
TW201132628A (en) 2011-10-01
BRPI0417609B8 (pt) 2021-05-25
DE602004023876D1 (de) 2009-12-10
US8778920B2 (en) 2014-07-15
EP1696914A1 (en) 2006-09-06
CN1893944A (zh) 2007-01-10
TW200530187A (en) 2005-09-16
EP1696914B1 (en) 2009-10-28
ATE446750T1 (de) 2009-11-15
CN1893944B (zh) 2011-07-06
US7655642B2 (en) 2010-02-02
IL176358A0 (en) 2006-10-05
KR101158440B1 (ko) 2012-07-06
ES2335216T3 (es) 2010-03-23
US20100069424A1 (en) 2010-03-18
US9040511B2 (en) 2015-05-26
UA83880C2 (en) 2008-08-26
AU2004298784A1 (en) 2005-06-30
NO337622B1 (no) 2016-05-09
AR047060A1 (es) 2006-01-04

Similar Documents

Publication Publication Date Title
ZA200604971B (en) 3-Cyano-quinoline derivatives with antiproliferative activity
SI1583763T1 (sl) Benzoazolilpiperazinski derivati, ki imajo VR1 antagonistično delovanje
IL174533A0 (en) Quinazoline derivatives as antiproliferative agents
AP1850A (en) Spiroindolineplperidine derivatives
EG24050A (en) Heterocylocarboxamide derivatives
HK1077068A1 (en) Azolidinone-vinyl fused-benzene derivatives
IL166121A0 (en) Indole-3-sulphur derivatives
EP1522540A4 (en) AZAARENE DERIVATIVES
HK1088602A1 (en) 2-pyridinecarboxamide derivatives
HK1088326A1 (en) Piperidine-benzenesulfonamide derivatives
PL375588A1 (en) Pyrimido compounds having antiproliferative activity
PL376475A1 (en) N-substituted-2-oxodihydropyridine derivatives
HK1089443A1 (en) Imidazol-4-yl-ethynyl-pyridine derivatives
GB0317665D0 (en) Qinazoline derivatives
PL1682493T3 (pl) Pochodne amidoacetonitrylu
HK1086842A1 (en) Macrolide-conjugates with anti-inflammatory activity
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
IL166426A0 (en) N-biarylmethyl aminocycloalkanecarboxamide derivatives
PL1706373T3 (pl) Pochodne amidoacetonitrylu
DE60326941D1 (en) Rs
EP1531854A4 (en) O-DERIVATED NOCATHIACIN DERIVATIVES
GB0319793D0 (en) Pyridinylmorpholine derivatives
GB0213488D0 (en) 2-Naphthamide derivatives
MY144310A (en) 3-cyano-quinoline deriatives with antiproliferative activity
AU2003225764A8 (en) Aza-thioxanthenones with antitumor activity